👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
Trust score 8/100
Accepting new patients
Prof
Prof Stephen Chan
Oncology
English
4,806+
Patients seen
6
Years in practice
13
Publications
1
Languages spoken
About
Prof. Stephen Chan is an experienced clinical oncologist based in Nottingham. He has a specialist interest in the treatment of breast and gynaecological cancers. He holds expertise and many years of experience in treating these conditions with chemotherapy and radiotherapy. He is a firm believer in personalised therapies for each of his patients.
He is a world leader in his field and is renowned for his innovative cancer research into the understanding and treatment of cancer. He has presented his work nationally and internationally.
Over the last 25 years, he has played a pivotal role in the discovery and licensing of a number of new chemotherapy treatments as well as novel targeted therapies. He is the senior author for over 100 research papers in world-renowned scientific journals and book chapters on new cancer drug development.
Professor Chan leads The Nottingham Personalised Therapy Oncology Research Group, and the Breast & Gynaecological Clinical Trial Group at the Nottingham University Hospital. The group's current interests include the development of new cancer genes and tests to select the best treatment for individual patients.
He is the Senior Author of two new publications in 2015 on a new Cancer Gene "HAGE"; and a new index " the Nottingham Prognostic Response Index". These are likely improve the treatment results of breast cancer with chemotherapy
Prof Chan qualified as a doctor at the Nottingham University Medical School and went on to focus his medical training in oncology through research and training at Oxford University. His cancer expertise was further heightened by his oncogenes research project at Cambridge MRC and the Imperial College London which allowed him a better, more influential understanding of the complex disease.
He is also a board member of the Maggie's charity in Nottingham.
Diseases, Medical Tests and Treatments
• Chemotherapy
• Radiotherapy IMRT, Breath Hold
• Targeted therapy
• Complementary Therapy
• Breast Cancer
• Gynaecological Cancers
• Ovarian Cancer
• Cervical Cancer
• Uterine Cancer
• Skin Cancer
He is a world leader in his field and is renowned for his innovative cancer research into the understanding and treatment of cancer. He has presented his work nationally and internationally.
Over the last 25 years, he has played a pivotal role in the discovery and licensing of a number of new chemotherapy treatments as well as novel targeted therapies. He is the senior author for over 100 research papers in world-renowned scientific journals and book chapters on new cancer drug development.
Professor Chan leads The Nottingham Personalised Therapy Oncology Research Group, and the Breast & Gynaecological Clinical Trial Group at the Nottingham University Hospital. The group's current interests include the development of new cancer genes and tests to select the best treatment for individual patients.
He is the Senior Author of two new publications in 2015 on a new Cancer Gene "HAGE"; and a new index " the Nottingham Prognostic Response Index". These are likely improve the treatment results of breast cancer with chemotherapy
Prof Chan qualified as a doctor at the Nottingham University Medical School and went on to focus his medical training in oncology through research and training at Oxford University. His cancer expertise was further heightened by his oncogenes research project at Cambridge MRC and the Imperial College London which allowed him a better, more influential understanding of the complex disease.
He is also a board member of the Maggie's charity in Nottingham.
Diseases, Medical Tests and Treatments
• Chemotherapy
• Radiotherapy IMRT, Breath Hold
• Targeted therapy
• Complementary Therapy
• Breast Cancer
• Gynaecological Cancers
• Ovarian Cancer
• Cervical Cancer
• Uterine Cancer
• Skin Cancer
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Prof Stephen Chan
Education & training
-
2010–2016 MD · Medicine and Surgery
-
2016–2020 Residency · Oncology
-
2020–2021 Fellowship · Subspecialty training
Career & appointments
-
2020-09–2021-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
Generali Healthcare · 4,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 1,955 |
| Annual physical exam | 99395 | 2,829 |
| Vaccination administration | 90471 | 365 |
| Minor procedure (skin) | 17110 | 714 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 120 min | in_clinic | 270.00 EUR |
| Minor procedure (skin) | 30 min | in_clinic | 360.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 14 · i10: 8
-
European registry analysis of Oncology outcomes
DOI: 10.2655/euroclin.2025.0 · PMID: 30673898 · cited by 3
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.8320/euroclin.2024.1 · PMID: 31788748 · cited by 57
-
European registry analysis of Oncology outcomes
DOI: 10.1278/euroclin.2023.2 · PMID: 35485173 · cited by 55
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
Society memberships
- WONCA Europe — Family Doctors — Member · since 2021
- national college of family doctors — Member · since 2021
- European Union of Medical Specialists (UEMS) — Member · since 2021
Patient reviews
- Bedside Manner
- 0.05
- Knowledge
- 0.08
- Wait Time
- 3.80
- Staff Friendliness
- 0.02
- Ease Of Appointment
- 4.00
- Value For Money
- 4.10
- Would Recommend Pct
- 4
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · professor.stephen.chan@euroclinics.example
